Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Rhea-AI Summary

Tevogen Bio (Nasdaq: TVGN) has filed a new patent titled 'Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models' to strengthen its IP portfolio. The company launched Tevogen.AI in October 2023 to enhance drug discovery, development, and manufacturing processes. Key developments include:

- Appointment of Mittul Mehta to lead Tevogen.AI
- Partnership with Microsoft through the Microsoft for Startups program in May 2024
- Successful application of machine learning for HPV target identification in November 2024
- Filing of International Application PCT/US2024/060419 on December 16, 2024

The company's ExacTcell™ technology aims to create CTL products targeting various viruses. Tevogen plans to provide additional updates at the J.P. Morgan Healthcare Conference in January 2025.

Positive

• Successfully integrated AI into drug development process, specifically for HPV target identification
• Strategic partnership with Microsoft through Startups program, gaining access to AI expertise
• Filed new AI-related patent to protect intellectual property
• ExacTcell technology demonstrates versatility in targeting multiple viruses

Negative

• None.

Insights

Medical Research Analyst

The patent filing for AI-driven peptide prediction represents an incremental step in Tevogen's technological development, but lacks immediate material impact. While the company's ExacTcellTM platform shows promise for T cell therapeutics, the current AI patent filing is primarily defensive and exploratory. The partnership with Microsoft, while notable, is through a startup program that many early-stage companies participate in.

The company's transition into HPV-related oncology applications marks a strategic expansion, but remains in early stages without clinical validation. Key metrics like development timelines, resource allocation and specific AI implementation strategies are notably absent from the announcement. The $60-110 billion market opportunity cited from McKinsey represents the entire pharma/medtech AI space, not Tevogen's addressable market.

For investors, while the long-term potential of AI in drug discovery is significant, this particular development represents more of a foundational building block rather than a near-term value driver. The upcoming J.P. Morgan Healthcare Conference presentation may provide more concrete metrics to evaluate the commercial viability of these initiatives.

Tech Expert

The AI patent filing focuses on machine learning models for peptide prediction, which is becoming increasingly common in the biotech industry. The technical implementation details and specific AI architectures remain undisclosed, making it difficult to assess the competitive advantage. The appointment of Mittul Mehta, while bringing relevant experience, doesn't necessarily indicate breakthrough AI capabilities.

The Microsoft partnership, while providing valuable resources, is through their startup program which offers standard-tier access to Azure services and support. The company's AI integration appears to be in early stages, with the HPV target identification being the only concrete application mentioned. The broader industry trend shows that successful AI implementation in drug discovery requires substantial data infrastructure and validation processes, which aren't addressed in this announcement.

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, filed for an additional patent, “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models”, as part of its developing intellectual property portfolio.

• In October 2023, Tevogen Bio launched its artificial intelligence effort, Tevogen.AI with the explicit goal to expedite enhancement of drug discovery, development, manufacturing, distribution, and patient access not only for Tevogen Bio’s efforts but also for other biotech companies.
• Later that month, Tevogen Bio appointed Mittul Mehta, with over 20 years of diverse experience in IT including over 10 years in senior management roles, to head Tevogn.AI. His cross-industry experience includes stints at Jefferies, MetLife, and Microsoft where his achievements underscored his ability to align technology with business goals.
• In December 2023, Tevogen Bio filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO), which was later converted to a PCT. Additionally, in December 2024, the company filed a second provisional application to further advance its artificial intelligence initiatives.
• In May 2024, Tevogen Bio entered a partnership with Microsoft (Nasdaq: MSFT) through the Microsoft for Startups program and gained access to experts and resources from a world-leading AI company.
• In November 2024, a direct impact of artificial intelligence effort was felt when machine learning was utilized for target identification to address Human Papilloma Virus (HPV). This signaled the start of Tevogen Bio’s oncology treatment pipeline. “Our ExacTcell^TM technology is adaptable and can create a spectrum of CTL products targeting a wide range of viruses, including HPV,” said Dr. Neal Flomenberg, Chief Scientific Officer at Tevogen Bio.
• On December 16, 2024, the International Application PCT/US2024/060419 was filed. “The filing of this patent further establishes our commitment to greater patient accessibility and quicker innovation while decreasing operating cost,” said Mr. Mehta. “Our AI initiative not only aligns with our company's mission but also positions us as a driving force for future advancements.” According to The McKinsey Global Institute, Generative AI could generate $60 billion to $110 billion annually in economic value for pharmaceutical and medtech companies.

“When combining our expertise across biopharma and artificial intelligence, we anticipate becoming a leader in the field with breakthroughs to follow,” said Tevogen Bio CEO Dr. Ryan Saadi, M.D., M.P.H. “We will provide additional updates about the company, including our AI effort, at the J.P. Morgan Healthcare Conference in January 2025.”

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen’s ability to develop additional product candidates, including through use of Tevogen’s ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen’s future clinical trials; and Tevogen’s ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the “Business Combination”) on Tevogen’s business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

What is the latest patent filed by Tevogen Bio (TVGN) in December 2024?

Tevogen Bio filed International Application PCT/US2024/060419 on December 16, 2024, focused on 'Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models'.

How is Tevogen Bio (TVGN) implementing AI in its drug development process?

Tevogen Bio launched Tevogen.AI in October 2023 to enhance drug discovery, development, manufacturing, distribution, and patient access. They've already utilized machine learning for HPV target identification in November 2024.

When did Tevogen Bio (TVGN) partner with Microsoft for AI development?

Tevogen Bio entered a partnership with Microsoft through the Microsoft for Startups program in May 2024, gaining access to AI experts and resources.

What is the potential economic impact of AI in pharmaceutical companies according to McKinsey?

According to The McKinsey Global Institute, Generative AI could generate $60 billion to $110 billion annually in economic value for pharmaceutical and medtech companies.